Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Canal

Showing results (101-110 of 142) with videos related to

Pageof 15
Sort By:
International Journal of Cancer|May 29, 1995
Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell linesA Nehmé, N Albin, M J Caliaro, et al.
British Journal of Cancer|May 1, 1994
Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamilA M Julia, H Roché, M Berlion, et al.
Journal of the National Cancer Institute|April 19, 1995
Prediction of carboplatin clearance from standard morphological and biological patient characteristicsE Chatelut, P Canal, V Brunner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantationM Attal, P Canal, D Schlaifer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective studyF Léger, S Séronie-Vivien, J Makdessi, et al.
British Journal of Cancer|January 1, 1997
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell linesM J Caliaro, P Vitaux, C Lafon, et al.
European Journal of Clinical Pharmacology|September 11, 2001
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in childrenA Patoux, N Bleyzac, A V Boddy, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Chronopharmacokinetics of doxorubicin in patients with breast cancerP Canal, A Sqall, M de Forni, et al.
American Journal of Clinical Oncology|February 1, 1997
Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I studyJ M Bachaud, E Chatelut, P Canal, et al.
British Journal of Cancer|July 17, 1999
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissuesS Guichard, C Terret, I Hennebelle, et al.
Pageof 15

Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
International Journal of Cancer|May 29, 1995
Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian-cancer cell linesA Nehmé, N Albin, M J Caliaro, et al.
British Journal of Cancer|May 1, 1994
Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamilA M Julia, H Roché, M Berlion, et al.
Journal of the National Cancer Institute|April 19, 1995
Prediction of carboplatin clearance from standard morphological and biological patient characteristicsE Chatelut, P Canal, V Brunner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantationM Attal, P Canal, D Schlaifer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective studyF Léger, S Séronie-Vivien, J Makdessi, et al.
British Journal of Cancer|January 1, 1997
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell linesM J Caliaro, P Vitaux, C Lafon, et al.
European Journal of Clinical Pharmacology|September 11, 2001
Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in childrenA Patoux, N Bleyzac, A V Boddy, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Chronopharmacokinetics of doxorubicin in patients with breast cancerP Canal, A Sqall, M de Forni, et al.
American Journal of Clinical Oncology|February 1, 1997
Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I studyJ M Bachaud, E Chatelut, P Canal, et al.
British Journal of Cancer|July 17, 1999
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissuesS Guichard, C Terret, I Hennebelle, et al.
Pageof 15